HWDN:LSEHowden Joinery Group PLC Analysis
Data as of 2026-03-11 - not real-time
£858.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Howden Joinery Group is trading above its 20‑day SMA (879.8 p) and 50‑day SMA (861.3 p) while both sit well above the 200‑day SMA (846.3 p), signaling a clear bullish alignment. The stock’s beta of 0.35 indicates low market‑related volatility, and volume is on an upward trend, supporting the bullish price action. RSI sits at 46, suggesting the price is not yet overbought, while the MACD histogram is negative, hinting at short‑term momentum weakness but not enough to offset the longer‑term trend. Fundamentally, the company posted an extraordinary 68.8% revenue growth and maintains a 62% gross margin, with operating and profit margins of 15.8% and 11% respectively. Return on equity is a healthy 23% and free cash flow remains positive, underpinning a sustainable dividend yield of 2.53% with a 43% payout ratio. The DCF model values the shares at ~£1,548 versus the current £858 price, implying roughly 17% upside, and analysts collectively rate the stock as a “buy” with median targets around £975. Recent insider purchases via the Share Incentive Plan add confidence, and market sentiment is in the “Extreme Greed” zone, further bolstering short‑term momentum.
Overall, the combination of strong growth metrics, solid cash generation, attractive dividend sustainability, and a valuation gap suggests the stock is **undervalued** and positioned for continued appreciation, especially if the broader consumer‑cyclical recovery gains pace.
Overall, the combination of strong growth metrics, solid cash generation, attractive dividend sustainability, and a valuation gap suggests the stock is **undervalued** and positioned for continued appreciation, especially if the broader consumer‑cyclical recovery gains pace.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 7/10
Key Factors
- Bullish SMA crossover and increasing volume
- Insider buying signals confidence
- MACD bearish divergence suggests caution
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust revenue growth and high margins
- Dividend yield with sustainable payout
- DCF‑based upside of ~17%
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Strong ROE and free cash flow generation
- Low beta indicating defensive characteristics
- Analyst consensus buy and attractive valuation gap
Key Metrics & Analysis
Financial Health
Revenue Growth68.80%
Profit Margin11.07%
P/E Ratio17.5
ROE23.08%
ROA9.51%
Debt/Equity75.88
P/B Ratio666.1
Op. Cash Flow£485.6M
Free Cash Flow£221.2M
Technical Analysis
TrendBullish
RSI46.3
Support£823.50
Resistance£981.00
MA 20£879.78
MA 50£861.30
MA 200£846.33
MACDBearish
VolumeIncreasing
Fear & Greed Index77.79
Valuation
Fair Value£1,548.41
Target Price£1,008.06
Upside/Downside17.49%
GradeUndervalued
TypeBlend
Dividend Yield2.53%
Risk Assessment
Beta0.35
Volatility40.70%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.